Logo wahanariau.com
  2. Israel

Israel

Index
Globenewswire

Patients Taking AUSTEDO XR® (deutetrabenazine) Extended-release Tablets Reported Symptom Improvement and High Satisfaction

Senin, 22 September 2025 - 02:25:11 Wib
Globenewswire

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

Senin, 22 September 2025 - 02:24:05 Wib
Globenewswire

Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual Meeting

Kamis, 18 September 2025 - 02:37:45 Wib
Globenewswire

Teva to Present at Morgan Stanley Global Healthcare Conference and Bank of America Global Healthcare Conference in September

Rabu, 03 September 2025 - 23:16:09 Wib
Globenewswire

Minovia Therapeutics Announces $350,000 Grant from Countdown for a Cure Foundation to Develop Mitochondria Blood-Based Biomarkers

Rabu, 27 Agustus 2025 - 23:19:59 Wib
Globenewswire

FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine

Kamis, 07 Agustus 2025 - 00:14:16 Wib
Globenewswire

Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 Revenue Outlook for Key Innovative Products and EPS, and Reaffirms All Other Components

Rabu, 30 Juli 2025 - 21:05:04 Wib
Globenewswire

Cellebrite Names David Barter Chief Financial Officer

Selasa, 08 Juli 2025 - 22:10:28 Wib
Globenewswire

Teva Releases Q2 2025 Aide Memoire

Jumat, 27 Juni 2025 - 03:41:22 Wib
Globenewswire

Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025

Jumat, 27 Juni 2025 - 03:23:49 Wib
Globenewswire

Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology

Senin, 16 Juni 2025 - 22:13:00 Wib
Globenewswire

Cellebrite to Acquire Corellium

Kamis, 05 Juni 2025 - 19:00:00 Wib
Globenewswire

Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer

Rabu, 04 Juni 2025 - 05:00:00 Wib
Globenewswire

Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total Maximum Amount and Election of Early Settlement

Selasa, 03 Juni 2025 - 18:30:00 Wib
Globenewswire

New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025

Senin, 02 Juni 2025 - 03:23:09 Wib
Globenewswire

Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with T

Senin, 02 Juni 2025 - 03:21:53 Wib
Globenewswire

Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA

Rabu, 28 Mei 2025 - 20:54:01 Wib
Globenewswire

Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference in June

Rabu, 28 Mei 2025 - 03:46:55 Wib
Globenewswire

Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatment of Atopic Dermatitis and Asthma

Selasa, 27 Mei 2025 - 20:00:00 Wib
Globenewswire

Teva Announces Increase of the Maximum Tender Amount of its Debt Tender Offer and Increases to Pool Tender Caps for Pool 2 Notes and Pool 3 Notes

Jumat, 23 Mei 2025 - 21:21:12 Wib
Globenewswire

Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing Debt

Kamis, 22 Mei 2025 - 04:04:00 Wib
Globenewswire

Fitch Ratings Agency Upgrades Teva Rating to BB+ Recognizing Successful Execution of Its Pivot to Growth Strategy

Kamis, 22 Mei 2025 - 04:02:24 Wib
Globenewswire

Teva Announces $2,000,000,000 (Equivalent) Debt Tender Offers For Notes Due 2026-2031

Senin, 19 Mei 2025 - 16:00:00 Wib
Globenewswire

Teva Announces Launch of $2,000,000,000 (Equivalent) Offering of Senior Notes

Senin, 19 Mei 2025 - 16:00:00 Wib
Globenewswire

Moody's Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy

Senin, 19 Mei 2025 - 02:26:40 Wib